Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 5/7/18

|Includes: Intra-Cellular Therapies Inc. (ITCI), STML, TXMD
Summary

This week's Marketplace postings include interviews with experts discussing assets from:STML, ITCI, TXMD.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Understanding The Unmet Need Of Patients With BPDCN And How Stemline’s Main Candidate, SL-401, Can Fit In This Space

Ticker:  STML

Call Date: 04/02/2018

Who's the Expert?

  • Deputy chair and professor of medicine in the Department of Leukemia.
  • Clinical interest focus on myelodysplatic syndromes, acute and chronic leukemias, and myeloproliferative disorders.
  • Author of over 700 published peer reviewed articles.

Interview Goal:

To gain a better understanding of Blastic Plasmacytoid Dendritic Cell Neoplasm from an expert’s point of view. This call will examine SL-401's potential based on the data available to date in treating this rare disease.

Link to original project page on Slingshot Insights with questions asked: link

TRANSCRIPT 2: Discussing possible implications for Intra-Cellular's lumateperone after ALKS' 5461 received a refuse to file from the FDA in MDD

Ticker: ITCI

Call Date: 04/04/2018

Who's the Expert?

  • Professor Psychiatry and Molecular Medicine at Hofstra Northwell School of Medicine & Medical Director of the Recognition and Prevention program at the Zucker Hillside Hospital.

  • Involved in the care of over 100 psychiatric patients per month in outpatient and inpatient settings; monthly treats ~20 patients with schizophrenia and depression (~7 bipolar), and ~6 with Tardive Dyskinesia per month.

  • Principal Investigator or Steering Committee member of several large, federally funded grants for antidepressants and novel mechanism agents for schizophrenia, bipolar disorder, major depressive disorder, and anxiety disorders.

Interview Goal:

To get an clinician's perspective on if investors should be more skeptical of lumateperone's chances at the FDA after Alkermes' alks-5461 received a refuse to file notification from the FDA. The letter said the RTF was:
"based on insufficient evidence of overall effectiveness for the proposed indication, and that additional well-controlled clinical trials are needed prior to the resubmission of the NDA for ALKS 5461."

There are potentially meaningful differences between the supportive data for the two drugs, but also similarities. This conversation will seek to better understand where lumateperone likely stands with the FDA.

Link to original project page on Slingshot Insights with questions asked: link

TRANSCRIPT 3: Exploring TherapeuticsMD's pipeline in treating VVA at hot flashes compared to existing therapies in the menopause space

Ticker: TXMD

Call Date: 04/04/2018

Who's the Expert?

  • Director of the Cleveland Clinic Center for Specialized Women’s Health and Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • Manages over 2,000 patients a year and ¾ have VVA/GSM and VMS/hot flashes.
  • Research focuses on leading edge and interdisciplinary therapies for women with a focus on menopausal and hormone risk assessment and therapies.

Interview Goal:
To discuss existing treatments options and new drugs for the class including:

  • TX-004HR/vaginal estradiol (Yuvvexy) for VVA
  • TX-001HR (a novel combination of 17ß-estradiol and progesterone) for vasomotor symptoms (VMS) related to menopause

Link to original project page on Slingshot Insights with questions asked: link

TRANSCRIPT 4: Another View:Exploring TherapeuticsMD's pipeline in treating VVA at hot flashes compared to existing therapies in the menopause space

Ticker: TXMD

Call Date: 04/06/2018

Who's the Expert?

  • Clinical Professor, OBGYN at Yale University;Board-certified obstetrician/gynecologist and author with an extensive background in women’s health issues.
  • Co-author of A Woman's Guide to Menopause and Perimenopause and The Yale Guide to Women's Reproductive Health as well as the author of articles in numerous peer-reviewed journals.
  • Treats several hundred women with VVA and hot flashes (15+ patients/week with VVA and dyspareunia); regularly prescribe estradiol and micronized natural progesterone..

Interview Goal:
To discuss existing treatments options and new drugs for the class including:

  • TX-004HR/vaginal estradiol (Yuvvexy) for VVA
  • TX-001HR (a novel combination of 17ß-estradiol and progesterone) for vasomotor symptoms (VMS) related to menopause

Link to original project page on Slingshot Insights with questions asked: link

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these interview and more : Link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.